Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Non-Current Assets (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Non-Current Assets for 4 consecutive years, with $93.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 7653.44% to $93.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $194.1 million through Dec 2025, up 4209.44% year-over-year, with the annual reading at $93.6 million for FY2025, 7653.44% up from the prior year.
  • Non-Current Assets hit $93.6 million in Q4 2025 for NewAmsterdam Pharma, up from $54.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $93.6 million in Q4 2025 to a low of $306000.0 in Q4 2023.
  • Historically, Non-Current Assets has averaged $28.4 million across 4 years, with a median of $1.3 million in 2024.
  • Biggest five-year swings in Non-Current Assets: crashed 99.64% in 2023 and later soared 7653.44% in 2025.
  • Year by year, Non-Current Assets stood at $85.1 million in 2022, then plummeted by 99.64% to $306000.0 in 2023, then skyrocketed by 294.44% to $1.2 million in 2024, then skyrocketed by 7653.44% to $93.6 million in 2025.
  • Business Quant data shows Non-Current Assets for NAMS at $93.6 million in Q4 2025, $54.1 million in Q3 2025, and $45.3 million in Q2 2025.